New FDA Guidance on Endpoints for Demonstrating Effectiveness of Drugs for Treatment of Opioid Use Disorder

December 10, 2020
Henry J. Riordan, PhD | Christine Moore, PhD | Christine Moore

Use and abuse of opioid products has increased alarmingly over the last 20 years. Read our article discussing the latest FDA guidance on the development of new drug treatments for opioid use disorder.

Your form has been successfully submitted! Click the button below to access.
VIEW PDF
Henry J. Riordan, PhD
MEET THE AUTHOR

Henry J. Riordan, PhD

Chief Development Officer
LEARN MORE
Christine Moore, PhD
MEET THE AUTHOR

Christine Moore, PhD

Vice President, Neuroscience, Scientific Solutions
LEARN MORE